Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics (AU:ZLD)
ASX:ZLD
ZLD Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$1.15
Previous CloseN/A
Volume190.00
Average Volume (3M)1.92K
Market Cap
AU$6.90M
Enterprise ValueAU$9.04M
Total Cash (Recent Filing)AU$5.66K
Total Debt (Recent Filing)AU$2.14M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding11,897,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Cannabinoid R&D And Regulated CommercializationA clear, focused business model on cannabinoid therapeutics and regulated commercialisation creates a durable platform: specialized R&D, clinical evaluation and regulatory pathways support differentiated products in chronic pain and related markets, enabling long-term commercial opportunity if clinical/regulatory milestones are met.
Slight Improvement In Free Cash Flow GrowthAn observed improvement in free cash flow growth, even from a negative base, indicates initial progress toward cash discipline. If sustained, this trend can lengthen runway, reduce incremental financing needs and support continued R&D or early commercial investment over the medium term.
Material EPS Improvement Year-over-yearA ~90% reported EPS growth suggests meaningful operational or accounting improvement versus the prior period. If this represents sustainable cost control or revenue stabilization, it signals potential progress toward profitability and stronger earnings power over the next several quarters.
Bears Say
Severe Revenue Collapse And Negative MarginsA near-total revenue collapse and persistently negative gross and operating margins are structurally harmful: they undermine ability to self-fund R&D and commercialization, increase dependency on external capital, and raise execution risk for clinical programs and market launches over the medium term.
Negative Stockholders' EquityNegative equity indicates accumulated losses and weak solvency, reducing financial flexibility. It can limit strategic options, increase borrowing costs, complicate partnerships or licensing, and heighten dilution risk from future raises—structural constraints that impede long-term execution.
Ongoing Negative Operating And Free Cash FlowPersistent negative operating and free cash flows reflect ongoing cash burn and the need for external financing. This creates durable execution risk: management must prioritize fundraising over growth, and repeated capital raises can dilute shareholders and disrupt multi-stage development programs.
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.31 and its highest was AU$1.15 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is AU$6.90M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 7 days.
How were Zelira Therapeutics’s earnings last quarter?
Zelira Therapeutics released its earnings results on Aug 29, 2025. The company reported -AU$0.104 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.104.
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Zelira Therapeutics reported an EPS of -AU$0.104 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.651%.
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-75.38%
Trailing 12-Months
Company Description
Zelira Therapeutics
Zelira Therapeutics (ZLD) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapeutics. Operating primarily in the healthcare sector, Zelira aims to address various health conditions, including chronic pain, sleep disorders, and other serious ailments. The company leverages its proprietary formulations and clinical research to create products that are designed to improve patient outcomes and quality of life.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―